Edison Issues Report On Mindmaze Therapeutics (MMTX)

2026-04-07 06:04:29

(MENAFN- Newsfile Corp) Edison Issues Report on MindMaze Therapeutics (MMTX)

April 07, 2026 5:41 AM EDT | Source: Edison Group

London, United Kingdom--(Newsfile Corp. - April 7, 2026) - Edison issues report on MindMaze Therapeutics (SIX: MMTX).

MindMaze Therapeutics is a commercial-stage health technology company pioneering AI-driven digital neurotherapeutic solutions for treatment and recovery after neurological events such as stroke and traumatic brain injury (TBI). Its unique, integrated and coordinated platform spans the full continuum of care from acute treatment to at-home recovery, providing differentiation and helping to avert treatment gaps. With US FDA and CE/MDR registrations and a unique US CPT Category III (CAT III) reimbursement for home-based therapy, MindMaze is primed for commercial roll-out across the US and Europe.

Click here

All reports published by Edison are available to download free of charge from its website:

Edison is authorised and regulated by the Financial Conduct Authority
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
...
+44 (0)20 3077 5700
Connect with Edison on:
LinkedIn
X
YouTube

To view the source version of this press release, please visit

Source: Edison Group

MENAFN07042026004218003983ID1110950904

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.